摘要
目的 探讨血清CA12 5和CEA联合检测在卵巢肿瘤诊断中的价值。 方法 采用酶联免疫分析法 (ELISA)对卵巢恶性肿瘤、良性肿瘤及子宫内膜异位症患者血清CA12 5和CEA含量进行检测。 结果 卵巢恶性肿瘤CA12 5含量明显高于对照组、卵巢良性肿瘤、交界性瘤及子宫内膜异位症 (P <0 0 1) ;子宫内膜异位症及盆腔炎CA12 5含量高于对照组及卵巢良性肿瘤 (P <0 0 5 )。 结论 单项检测CA12 5对卵巢上皮性癌诊断性能最佳 ,对子宫内膜异位症也有较理想的诊断价值。CA12 5、CEA联合检测对卵巢恶性肿瘤的诊断无明显价值。
Objective To study the diagnosis value of combined measurement of the cancer antigen 125(CA125) and CEA in patients with ovarian tumors.Methods ELISA was used to measure the levels of serum CA125 and CEA in patients with benign ovarian tumor, malignant ovarian tumor and endometriosis.Results Serum CA125 level was significantly higher in patients with malignant ovarian tumor than that in those with benign or borderline ovarian tumor or endometriosis and in normal controls (P< 0.01 ). Serum CA125 level was higher in patients with endometriosis and pelvic infection than that in those with benign ovarian tumor and in normal controls (P<0.05).Conclusion The single detection of CA125 may be the best method for diagnosing ovarian epithelioma and has greater value in diagnosing endometriosis. The combined detection of CA125 and CEA doesn't have significant value in diagnosing malignant ovarian tumor.
出处
《医药论坛杂志》
2003年第23期1-2,4,共3页
Journal of Medical Forum
